https://orcid.org/0000-0002-0890-3197
Citations (9)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Mikkel Højlund & Christoph U. Correll. (2023) Switching to long-acting injectable antipsychotics: pharmacological considerations and practical approaches. Expert Opinion on Pharmacotherapy 24:13, pages 1463-1489.
Read now
Read now
Chesika J. Crump, Megan E. Good, Hagar Abuelazm & Rif S. El-Mallakh. (2023) Narrative review of the advances in the pharmacotherapeutic management of juvenile-onset schizophrenia. Expert Opinion on Pharmacotherapy 24:9, pages 1039-1052.
Read now
Read now
Mansour Adam Mahmoud, Md Ashraful Islam, Malaz Ahmed, Randa Bashir, Romisa Ibrahim, Shahd Al-Nemiri, Ethar Babiker, Neven Mutasim, Sultan Othman Alolayan, Sultan Al Thagfan, Samrein B M Ahmed, Ibrahim Sales, Mohamed Azmi Hassali, Yaser Alahmadi & Mirghani A Yousif. (2021) Validation of the Arabic Version of General Medication Adherence Scale (GMAS) in Sudanese Patients with Diabetes Mellitus. Risk Management and Healthcare Policy 14, pages 4235-4241.
Read now
Read now
Articles from other publishers (6)
Yanlin Wang, Matthew Harlin, Frank Larsen, Xiaofeng Wang, Wansu Park, Benjamin Rich, Jogarao V. Gobburu & Arash Raoufinia. (2024) Population Pharmacokinetics and Dosing Simulations for Aripiprazole 2‐Month Ready‐to‐Use Long‐Acting Injectable in Adult Patients With Schizophrenia or Bipolar I Disorder. Clinical Pharmacology in Drug Development.
Crossref
Crossref
Laura Orsolini, Sofia Pacini Biagiotti, Lorenzo Maria Martino & Umberto Volpe. (2024) A case report of LAI two injection start in a 16-year-old adolescent with severe manic episode and comorbid cannabinoid use disorder. Asian Journal of Psychiatry 94, pages 103992.
Crossref
Crossref
MIQUEL BIOQUE, MARÍA JOSÉ MORENO, SUSANA GÓMEZ-LUS & MARÍA ISABEL RAMOS. (2024) Clinical Experience on the Use of a Single-day, Two-injection Start Initiation Regimen of Aripiprazole Once Monthly in Patients With Schizophrenia in Spain: SaTISfy Study. Journal of Psychiatric Practice 30:2, pages 82-94.
Crossref
Crossref
Enrique Bandín-Vilar, Francisco José Toja-Camba, María Vidal-Millares, María José Durán-Maseda, Marta Pou-Álvarez, Ana Castro-Balado, Olalla Maroñas, Almudena Gil-Rodríguez, Ángel Carracedo, Irene Zarra-Ferro, Dolors Soy, Anxo Fernández-Ferreiro, Víctor Mangas-Sanjuan & Cristina Mondelo-García. (2024) Towards precision medicine of long-acting aripiprazole through population pharmacokinetic modelling. Psychiatry Research 333, pages 115721.
Crossref
Crossref
Alessandro Cuomo, Eugenio Aguglia, Stefano Biagini, Alessandro Carano, Massimo Clerici, Armando D'Agostino, Sergio De Filippis, Serafino De Giorgi, Arianna Goracci, Claudia Libri, Francesco Lombardi, Matteo Lupi, Giuseppe Maina, Giovanni Martinotti, Pietro Nigro, Mauro Pettorruso, Valerio Ricci, Eros Rossi, Felicia Russo & Andrea Fagiolini. (2023) Two-Injection Start Regimen of Long-Acting Aripiprazole in 133 Patients With Schizophrenia. Journal of Clinical Psychopharmacology 43:1, pages 35-38.
Crossref
Crossref
Daniel Schöttle, Guerline Clerzius, Wolfgang Janetzky, Oloruntoba Oluboka, Marc-André Roy, François Therrien & Klaus Wiedemann. (2022) Real-world effectiveness of aripiprazole once-monthly REACT study: Pooled analysis of two noninterventional studies. European Psychiatry 65:1.
Crossref
Crossref